Tranzactioneaza Intellia Therapeutics (US.NTLA) - 13.97 USD (%) Tranzactioneaza
Indici
Descriere companie
Intellia Therapeutics, Inc. (http://www.intelliatx.com/) is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. The Company's CRISPR/Cas9 is a technology for genome editing, process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To fully realize the transformative potential of CRISPR/Cas9, the Company uses two primary approaches. The Company’s in vivo programs use intravenously administered CRISPR as the therapy, in which its delivery technology enables precise editing of disease-causing genes directly within specific target tissues. The Company’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.